NNFL Read More Ravens’ Unofficial Depth Chart Heading Into Training CampJune 30, 2025 Noteboom was signed during the offseason to be the sixth lineman and swing tackle. Vorhees enters camp as…
NNutrition Read More Health effects associated with consumption of processed meat, sugar-sweetened beverages and trans fatty acids: a Burden of Proof studyJune 30, 2025 Monteiro, C. A. et al. Ultra-processed foods: what they are and how to identify them. Public Health Nutr.…
GGenetics Read More Structural variants in the 3D genome as drivers of diseaseJune 30, 2025 Kaschta, D. et al. Evaluating genome sequencing strategies: trio, singleton, and standard testing in rare disease diagnosis. Preprint…
PPhysics Read More Single-shot spatiotemporal vector field measurements of petawatt laser pulsesJune 30, 2025 Physical encoder Most ultraintense lasers approximate an ideal top-hat intensity profile in the near field, which when focused…
GGenetics Read More How and when organisms edit their own genomesJune 29, 2025 Lindahl, T. Instability and decay of the primary structure of DNA. Nature 362, 709–715 (1993). Article CAS PubMed …
NNFL Read More Ravens Can Handle the Heat of High ExpectationsJune 28, 2025 It’s been so hot and humid this week, I’m sure the Ravens are grateful that training camp hasn’t…
PPhysics Read More Dynamic phase transition in 1T-TaS2 via a thermal quenchJune 28, 2025 Thompson, A. H., Gamble, R. F. & Revelli, J. F. Transitions between semiconducting and metallic phases in 1-T…
GGenetics Read More Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian BiobankJune 27, 2025 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and Longer-Term Outcomes…
TTechnology Read More Guilty Gear creator reveals new project… but it’s definitely not a fighting gameJune 27, 2025 Arc System Works is looking to step outside of their comfort zone with new and…
GGenetics Read More AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trialJune 27, 2025 Study design and oversight This ongoing, nonrandomized, open-label, ascending-dose, phase 1b study (ClinicalTrials.gov registration no. NCT03362502) was initiated…